...
首页> 外文期刊>Transplantation Proceedings >High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: Experiences of a randomized prospective single-center study
【24h】

High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: Experiences of a randomized prospective single-center study

机译:肾移植中早期类固醇戒断和无钙调磷酸酶抑制剂的维持治疗的方案中排斥反应发生率高且西罗莫司耐受性差:随机前瞻性单中心研究的经验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Immunosuppressive maintenance therapy after kidney transplantation leads to various undesired side effects such as calcineurin inhibitor (CNI)-associated nephrotoxicity or elevated cardiovascular risk due to posttransplantation diabetes and hypertension. These effects show negative impacts on long-term allograft function as well as patient morbidity and mortality. Therefore, we used an immunosuppressive regimen with early corticosteroid withdrawal (ESW), maintenance therapy containing tacrolimus, sirolimus (SRL), and mycophenolate sodium for 3 months followed by a prospective randomized trial comparing a CNI free versus a low-dose CNI therapy. The primary endpoint was 6-month graft function. Among 75 patients, ESW was performed after 4 days in 65 patients. Over the following 3 months before randomization to CNI-free maintenance therapy, we experienced a high number (25%) of SRL discontinuations due to adverse events, including leukopenia, anemia, arthritis, and pneumonitis. In addition there were significantly more allograft rejection episodes in the CNI-free group (P =.017) during the study period leading to a switch from SRL to a CNI. Despite the higher rate of rejection episodes in the CNI-free groups, glomerular filtration rates (GFR) at 6 months were comparable between the study groups (P =.25). After 1 year only 9.2% (6/65) of all patients treated with SRL remained on this drug. Conclusion, there was an unacceptably high rate of SRL intolerance using an ESW and CNI-free immunosuppressive regimen combined with a significantly higher rate of rejection episodes.
机译:肾脏移植后的免疫抑制维持疗法会导致各种不良副作用,例如钙调神经磷酸酶抑制剂(CNI)相关的肾毒性或由于移植后糖尿病和高血压引起的心血管风险升高。这些效果显示出对同种异体长期移植功能以及患者发病率和死亡率的负面影响。因此,我们采用了免疫抑制方案,即早期停用糖皮质激素(ESW),包含他克莫司,西罗莫司(SRL)和麦考酚酸钠的维持治疗3个月,然后进行了一项前瞻性随机试验,比较了无CNI和低剂量CNI治疗。主要终点是6个月的移植功能。在75例患者中,有65例患者在4天后进行了ESW。在接下来的3个月中,在随机分配至无CNI的维持治疗之前,由于不良事件(包括白细胞减少症,贫血,关节炎和肺炎),我们经历了大量(25%)的SRL停药。此外,在研究期间,无CNI组的同种异体移植排斥事件明显增多(P = .017),导致从SRL转向CNI。尽管无CNI组的排斥反应发生率较高,但研究组之间在6个月时的肾小球滤过率(GFR)相当(P = .25)。一年后,所有用SRL治疗的患者中仅9.2%(6/65)仍使用该药物。结论:使用无ESW和无CNI的免疫抑制方案以及显着更高的排斥反应发生率,存在不可接受的SRL不耐受率。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号